High frequency of altered HLA class I phenotypes in invasive breast carcinomas

Human Immunology

Volumn 50, Issue 2, 1996, Pages 127-134

  Cabrera, Teresa ^a   Fernandez, Maria Angustias ^a   Sierra, Angels ^b   Garrido, Antonio ^a   Herruzo, Alfonso ^a   Escobedo, Agustin ^c   Fabra, Angels ^b   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; GENE LOSS; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOGENETICS; IMMUNOHISTOLOGY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030272636     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/0198-8859(96)00145-0     Document Type: Article

References (29)

1. 1. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern P: Natural history of HLA antigens during tumor development. Immunol Today 14:491, 1993.
2. 2m gene expression. J Clin Invest 87:248, 1991.
3. 3. Blanchet O, Bourge JF, Zinszner H, Tatari Z, Degos L, Paul P: DNA binding of regulatory factors interacting with MHC class I gene enhancer correlates with MHC class I transcription level in class I defective cell lines. Int J Cancer (Suppl)6:138, 1991.
4. 4. Marincola FM, Shamamiam P, Alexander RB, Ferrone S: Loss of HLA haplotype and B locus down regulation in melanoma cell lines. J Immunol 153:1225, 1994.
5. 5. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F: Phenotypic and genetic analysis of HLA class I and HLA DR antigen expression on human melanomas. Exp Clin Immunogenet 5:203, 1987.
6. 6. Esteban F, Concha A, Huelin C, Sanchez Rozas JA, Pedrinaci S, Ruiz-Cabello F, Garrido F: Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 43:436, 1989.
7. 7. Browning MJ, Krausa P, Rowan A, Hill AB, Bicknell DC, Bodmer JG, Bodmer W: Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for antitumor immunity and immunotherapy. J Immunother 14:163, 1993.
8. 8. Lopez-Nevot MA, Esteban F, Ferron A, Gutierrez J, Oliva MR, Romero C, Huelin C, Ruiz-Cabello F, Garrido F: HLA class I gene expression on human primary tumors and autologous metastasis: Demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59:221, 1989.
9. 9. Fleming KA, McMichael A, Morton JA, Woods J, McGee JO'D: Distribution of HLA class I antigens in normal human tissue and in mammary cancer. J Clin Pathol 34; 779, 1981.
10. 10. Pérez M, Cabrera T, López Nevot, MA, Gomez Morales M, Perán F, Ruiz-Cabello F, Garrido F: Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J Immunogenet 13:247, 1986.
11. 11. Natali PG, Giacomini P, Bigotti A, Imai K. Nicotra AK, Ng, Ferrone S: Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 43;660, 1983.
12. 12. Möller P. Mattfeldt T. Gross C. Schlosshauer P. Koch A. Koretz K. Moldenhauer G. Kaufmann M. Otto HF: Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (li) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am J Pathol 135:73, 1989.
13. 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer 62: 289, 1990.
14. 14. Concha A, Cabrera T, Ruiz-Cabello F, Garrido F: Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer (Suppl)6:146, 1991.
15. 15. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F: Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2:47, 1991.
16. 16. Maiorana A, Cesinaro AM, Fano RA, Collina G: Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metastas 13:43, 1995.
17. 17. Barnstable CJ, Bodmer WF, Brown G, Galfre BB, Milstein C, Williams AF, Ziegler A: Production of monoclonal antibodies to group A erythrocyte HLA and other human cell surface antigens-new tool for genetic analysis. Cell 14:9, 1978.
18. 18. Lopez-Nevot MA, Cabrera T, de la Higuera B, Ruiz-Cabello F, Garrido F: Production and characterization of monoclonal antibodies against leukemic cells. Immunologia 5:51, 1986.
19. 19. Spear BT, Kornbluth J, Strominger JL, Wilson DB. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131. J Exp Med 162:1802, 1985.
20. 1 domain of HLA-A molecules. Immunogenetics 30:50, 1989.
21. 21. Burrone OR, Fefford RF, Gilmore D, Milstein C: Stimulation of HLA ABC by IFN. The derivation of Molt 4 variant and the differential expression of HLA ABC subset. EMBO J 4:2855, 1985.
22. 22. Cabrera T, Ruiz-Cabello F, Lopez-Nevot MA, de la Higuera B, Sanchez M, Garrido F: Characterization of monoclonal antibodies directed against HLA class II molecules. Hybridoma 5:191, 1986.
23. 23. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340, 1995.
24. 24. Seung S, Urban JL, Schreiber H: A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 178:933, 1993.
25. 25. Keating PJ, Cromm FV, Duggan-Keen M, Snijders PJF, Walboomers JMM, Hunter RD, Dyer PA, Stern PL: Frequency of down regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405, 1995.
26. 26. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CRM, Rizza CR, McMichael AJ: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453, 1991.
27. 27. Hill AVS, Elvin J, Willis AC, Aidoo M, Allsopp CEM, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend ARM, McMichael AJ, Whittle HC: Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434, 1992.
28. 28. Ellis JRM, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, Stern PL: The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Med 1:464, 1995.
29. 29. Casey G, Plummer S, Hoeltge G, Scanlon D, Fasching C, Stanbridge EJ: Functional evidence for a breast cancer growth suppressor gene on chromosome 17. Hum Mol Genet 2:1921, 1993.